CurrentBlue Cross Blue Shield - IllinoisPolicy CPCPLABO32

Oral Cancer Screening and Testing

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Illinois Policy CPCPLABO32 alerts

Get alerted when Policy CPCPLABO32 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines Blue Cross Blue Shield Illinois reimbursement stance for laboratory and diagnostic testing used to screen, detect, or establish HPV tumor status in oral and oropharyngeal cancers; applies to providers submitting claims to BCBSIL for covered members.

Policy Summary

PayerBlue Cross Blue Shield - Illinois

PolicyOral Cancer Screening and Testing

Policy CodePolicy CPCPLABO32

Change TypeNew policy

Effective DateSep 25, 2025

Last ReviewSep 25, 2025

Next Review Date

Key ActionSubmit accurate documentation and use valid HIPAA-approved code sets; claims may be reviewed and require additional documentation upon request.

SourceLink

POLICY UPDATE CHANGES

New policy establishing coverage criteria for oral cancer screening and HPV tumor testing.

Version 1.0policy version

1new policy effective date listed

HPV testing reimbursable

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Cross Blue Shield - IllinoisPolicy CPCPLABO32

Oral Cancer Screening and Testing

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Illinois Policy CPCPLABO32 alerts

Get alerted when Policy CPCPLABO32 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Cross Blue Shield - Illinois

PolicyOral Cancer Screening and Testing

Policy CodePolicy CPCPLABO32

Change TypeNew policy

Effective DateSep 25, 2025

Last ReviewSep 25, 2025

Next Review Date

Key ActionSubmit accurate documentation and use valid HIPAA-approved code sets; claims may be reviewed and require additional documentation upon request.

SourceLink

POLICY UPDATE CHANGES

New policy establishing coverage criteria for oral cancer screening and HPV tumor testing.

Version 1.0policy version

1new policy effective date listed

HPV testing reimbursable

Coverage Criteria for Oral Cancer Testing

Oral cancer testing coverage criteria

Reimbursement guidance for oral cancer-related testing

ALL of the following

ONE of
- Testing to establish HPV tumor status for individuals with oropharyngeal squamous cell carcinoma or with metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node is requested.
- High-risk HPV testing is performed using either mRNA expression testing for HPV E6/E7 or immunohistochemistry.

ALL of the following

ANY of the following
- Metabolite tests are used to screen, detect, or diagnose oral cancer.
- Panels that incorporate genetic risk factors with nongenetic biomarkers (for example, mRNA CancerDetectTm) are used for screening, detection, or diagnosis of oral cancer.
- Detection of HPV from an oropharyngeal swab such as the OmniPathology Oropharyngeal HPV PCR Test is used to screen, detect, or diagnose oral cancer.

Procedure Codes

Procedure codesmixed

Procedure codes referenced but not listed; inclusion does not guarantee coverage.

Documentation and Claim Submission Requirements

Documentation Required

Documentation and Claim Submission Requirements

Providers are responsible for submitting accurate and complete documentation for services performed and for submitting claims using valid, HIPAA-approved code sets. Claims must be coded according to industry-standard coding guidelines (including but not limited to Uniform Billing, AMA CPT, HCPCS, ICD-10-CM/PCS, NDC, DRG rules, and CMS National Correct Coding Initiative guidance). Drug and laboratory submissions are subject to claim review and may be adjudicated based on benefit coverage, provider contract terms, applicable medical and clinical payment and coding policies, and internal coding logic. Upon request, providers must furnish additional documentation to support the claim.

Submit claims using HIPAA-approved code sets (CPT, HCPCS, ICD-10, NDC, Revenue, Modifiers) and follow industry coding guidance.
Ensure documentation supports services billed, including medical records, lab orders, test results, and physician sign-off where required.
Drug and lab claims may be reviewed for benefit coverage, contract terms, policy compliance, and coding software logic — be prepared to provide supporting records.
Adhere to CMS NCCI edits, Local/National Coverage Determinations, and other applicable CMS guidelines when applicable.
Failure to provide requested documentation may result in claim denial or recoupment.

Definitions — Reimbursable and Non-reimbursable Tests

inv-04: Testing to establish HPV tumor status (mRNA E6/E7 expression or immunohistochemistry)

Test purposeEstablish HPV tumor status for individuals with oropharyngeal squamous cell carcinoma or with metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node.

Acceptable methodsHigh‑risk HPV testing using either mRNA expression testing for HPV E6/E7 or immunohistochemistry.

Clinical contextUsed when determining tumor HPV status in oropharyngeal SCC or metastatic SCC of unknown primary to guide diagnosis and management.

Reimbursement stanceMay be reimbursable when performed for the stated clinical indications.

inv-05: Non-reimbursable oral cancer screening tests

Non‑reimbursable: metabolites